Results 71 to 80 of about 921,366 (160)
Leishmania Extracellular Vesicles as a Preventive Vaccine Platform Against Leishmaniasis
The potential of Leishmania‐derived extracellular vesicles (EVs) as a vaccine platform was investigated, emphasizing an affordable, GMP‐compliant production and purification method. Immunization with EV vaccines, either unadjuvanted or combined with α‐galactosylceramide (αGC), induced robust humoral and cellular immune responses, conferring protection ...
Ismail Cem Yilmaz +24 more
wiley +1 more source
Yonghui Liu,1 Zhaoyu Wang,1 Fan Yu,2 Mingjing Li,1 Haomiao Zhu,1 Kun Wang,1 Meng Meng,1 Wei Zhao1 1State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and KLMDASR of Tianjin, Nankai University, Tianjin 300353, People’s Republic ...
Liu Y +7 more
doaj
Heparan Sulfate Proteoglycans in Immunity
ABSTRACT In immune cells, heparin was first identified in mast cells in the 1940s, followed by the discovery of heparan sulfate in lymphocytes and granulocytes during the 1970s and 1980s. Subsequent decades of research have revealed how heparan sulfate and heparin, conjugated to core proteins as heparan sulfate proteoglycans (HSPGs), act as versatile ...
Moe Iwai, Pyong Woo Park
wiley +1 more source
The aim of this study was to investigate and compare the immunogenicity of liposome-forming, sustained release lipid implants containing either an α-galactosylceramide (α-GalCer) analogue, imiquimod or Quil-A (QA) as adjuvants.
Hook, Sarah +4 more
core +1 more source
The glycolipid‐peptide antigen complexes for self‐adjuvanting conjugates were successfully synthesized, and, with the HLA‐transgenic mice, the antigen‐specific CD8+ T cell expansion was exhibited. The results provide useful insights for the design and synthesis of vaccine conjugates using glycolipid antigen as an adjuvant.
Shunya Kikuchi +4 more
wiley +1 more source
Dual Modifications of α-Galactosylceramide Synergize to Promote Activation of Human Invariant Natural Killer T Cells and Stimulate Anti-tumor Immunity [PDF]
© 2018 Elsevier Ltd Glycosylceramides that activate CD1d-restricted invariant natural killer T (iNKT) cells have potential therapeutic applications for augmenting immune responses against cancer and infections.
Wen, Xiangshu +12 more
core +1 more source
We present the first high‐quality annotated genome of Pinna rudis and an updated genome assembly for Pinna nobilis, two Mediterranean fan mussel species differentially affected by mass mortality events. Comparative genomic analyses of gene sets associated with the “defensome” show that these genes are largely functionally conserved between the two ...
Stéphane Coupé +6 more
wiley +1 more source
Organoids for Metabolic Disease Modeling
ABSTRACT Inherited metabolic diseases (IMDs) are a diverse group of rare genetic disorders that disrupt metabolic pathways, leading to severe clinical manifestations. Disease models ranging from complex animal models to simple in vitro systems have provided insights into IMDs, but each has limitations.
Arif Ibrahim Ardisasmita +2 more
wiley +1 more source
In this study, we characterize a distinct subpopulation of undifferentiated invariant natural killer T (iNKT) cells in the peripheral blood of healthy adults, which are characterized by CD38 expression in a resting state. This CD38+ subset closely resembles iNKT cells from cord blood and thymus, exhibiting a unique cytokine profile and alterations in ...
Christopher Menne +13 more
wiley +1 more source
In-vivo stimulation of macaque natural killer T cells with α-galactosylceramide
Fulltext embargoed for: 12 months post date of publicationNatural killer T cells are a potent mediator of anti-viral immunity in mice, but little is known about the effects of manipulating NKT cells in non-human primates. We evaluated the delivery of the
Jegaskanda, S +3 more
core +1 more source

